Navigation Links
BBVA Foundation Unites the Efforts of Massachusetts General Hospital and Barcelona's Vall d'Hebron Hospital in Biomarker Research for Personalized Cancer Therapies
Date:11/16/2011

MADRID, Nov. 16, 2011 /PRNewswire/ -- The BBVA Foundation announced an agreement to underwrite a joint effort between Massachusetts General Hospital and Barcelona's Vall d'Hebron Hospital to search for personalized cancer therapies through biomarker research.

The BBVA Foundation Tumor Biomarkers Research Program will provide 2.5 million euros over the next five years to fund the collaborative efforts of MGH and VHIO.  MGH has also committed to match up to 1.25 million euros of the BBVA Foundation contribution.  Funding for the research may be increased according to economic circumstances and as need arises.

"We are grateful that the BBVA Foundation is not only maintaining but boosting its support for this program, along with its broader commitment to research in general, and cancer research in particular, at a time of economic difficulties," said Josep Baselga, chief of hematology/oncology at MGH.

BBVA Foundation President Francisco Gonzalez concurred, adding: "Spain cannot afford to slip behind in an area where it has already attained a position of some prominence, and where research results can drive tangible improvements in the diagnostic and therapeutic options available to patients."  

BBVA Foundation President and BBVA CEO Francisco Gonzalez, Josep Baselga, Chief of Hematology/Oncology at Massachusetts General Hospital Cancer Center, and Andres de Kelety, managing director at the Vall d'Hebron Institute of Oncology signed the agreement creating the program Monday in Barcelona. Also attending the event was the BBVA Foundation Director Rafael Pardo.

Biomarkers are biological characteristics of malignant cells that are measurable in tumor tissue and, at times, in blood. Biomarkers can measure alterations of the genome, of the proteins encoded by the genome and at times enzymes or metabolites. The information they give can be prognostic – how the disease is likely to evolve – or predictive – how it may respond to a given treatment. Studies in this case will initially center on colorectal, breast and lung cancer, with likely expansion into melanomas, lymphomas, and prostate cancer.

For more information on the BBVA Foundation, please visit http://www.fbbva.es/TLFU/tlfu/ing/home/index.jsp.


'/>"/>
SOURCE BBVA Foundation
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. John Grisham Joins Focused Ultrasound Surgery Foundation Board, Citing Novel Technologys Potential to Help Millions of Patients
2. ABMAC Foundation Announces Publication of an Historic Volume Documenting the Creation of a National Health Care System in Taiwan
3. Assay Designs(TM), Inc. and the Spinal Muscular Atrophy Foundation Announce Collaboration To Accelerate the Discovery of New Therapeutics for Spinal Muscular Atrophy (SMA)
4. diaDexus, Inc. and Living Heart Foundation Offer the PLAC(R) Test to Detect Hidden Risk for Heart Attack and Stroke in Retired NFL Players
5. Ameristar National Charity Golf Classic Raises More Than $1.1 Million for Buoniconti Fund to Cure Paralysis and Christopher & Dana Reeve Foundation
6. Former Scientific Director at Genomics Institute of Novartis Research Foundation Named President of Cell Therapeutics Europe
7. GBS/CIDP Foundation to Hold 10th International Symposium
8. Mirixa Corporation and the APhA Foundation Form Partnership
9. BIO Ventures for Global Health Receives $7 Million Grant from Gates Foundation to Engage Biotechnology in the Fight Against Neglected Diseases of the Developing World
10. Michael J. Fox Foundation Awards $2 Million Grant From EMD Serono to Research Projects on Cognitive Deficits in Parkinsons Disease
11. Canary Foundations Dr. Sanjiv Sam Gambhir Elected to the National Academies Institute of Medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... June 23, 2016 , ... ... launch of the Supplyframe Design Lab . Located in Pasadena, Calif., the ... future of how hardware projects are designed, built and brought to market. , ...
(Date:6/23/2016)... , June 23, 2016 Apellis Pharmaceuticals, ... 1 clinical trials of its complement C3 inhibitor, ... and multiple ascending dose studies designed to assess ... of subcutaneous injection in healthy adult volunteers. ... either as a single dose (ranging from 45 ...
(Date:6/23/2016)... On Wednesday, June 22, 2016, the NASDAQ Composite ... Jones Industrial Average edged 0.27% lower to finish at 17,780.83; ... has initiated coverage on the following equities: Infinity Pharmaceuticals Inc. ... NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ ), ... more about these stocks by accessing their free trade alerts ...
(Date:6/23/2016)... ... June 23, 2016 , ... Velocity Products, ... tools designed, tuned and optimized exclusively for Okuma CNC machining centers at The ... of a collaboration among several companies with expertise in toolholding, cutting tools, machining ...
Breaking Biology Technology:
(Date:6/9/2016)... -- Perkotek an innovation leader in attendance control systems is proud to announce the introduction ... to make sure the right employees are actually signing in, and to even control ... ... ... ...
(Date:6/2/2016)... June 2, 2016 The Department of ... awarded the 44 million US Dollar project, for the ... Plates including Personalization, Enrolment, and IT Infrastructure , ... the production and implementation of Identity Management Solutions. Numerous renowned ... Decatur was selected for the most ...
(Date:5/24/2016)... Calif. , May 24, 2016 Ampronix facilitates superior patient care by ... LMD3251MT  3D medical LCD display is the latest premium product recently added to the ... ... ... Sony 3d Imaging- LCD Medical Display- Ampronix News ...
Breaking Biology News(10 mins):